Innoen 20% Glucose Injection

Adult administration

Administer 20-500 mL intravenously at a time. The rate of intravenous infusion should be less than 0.5 g/kg per hour as dextrose. Use an appropriate amount for dissolving and diluting the injection preparation. Adjust dosage according to age and symptoms.

This drug may carry a risk of glass particle contamination when using ampule injections, so great caution is needed when breaking the container. Extra vigilance is particularly required when used in children or the elderly. Patients receiving intravenous injections containing dextrose should be cautious as vitamin B1 (thiamine) deficiency may occur rapidly. This drug should not be administered to patients with certain conditions such as storage dehydration, fluid overload, hyperglycemia, acidosis, hypokalemia, hyperosmolar coma, or intolerance to glucose. Additionally, it should not be used in patients with anuria, hepatic coma, or those showing hypersensitivity to this drug, nor should it be administered in hypertonic form to patients with spinal or intracranial hemorrhage. Care should be taken when administering to patients expected to have deficits of potassium, phosphate, or magnesium, or those with hyponatremia, diabetes insipidus, renal failure, heart failure, severe malnutrition, sepsis, major trauma, or shock. Administering large volumes of this drug rapidly may cause electrolyte imbalance or fluid overload; caution is required. Administration in excess of the recommended dose may lead to elevated levels of bilirubin and lactic acid, as well as conditions such as hypokalemia, hyperosmolar coma, acidosis, dehydration, and hyperosmolarity. Intravenous administration may cause fluid overload and electrolyte imbalance, congestion, and pulmonary edema, while patients with glucose intolerance may experience hyperglycemia and renal loss. Signs of heat, phlebitis, thrombosis, and pain may appear at the injection site, and symptoms of uremia should also be monitored. Long-term use may affect insulin production, thereby necessitating the administration of insulin as needed. In patients post-surgery or trauma, or those with glucose intolerance, a lower concentration solution should be administered under blood glucose control. During administration, monitoring of serum electrolyte tests, blood glucose concentration, and the patient's condition is crucial. Safety of this medication has not been established during pregnancy, hence risks to the fetus versus therapeutic benefits should be carefully considered. Use during labor carries a risk of hyperglycemia or hypoglycemia, and metabolic acidosis for the mother and newborn, thus caution is necessary. In children, due to lower ability to regulate electrolytes and fluids, plasma electrolyte levels should be closely monitored, especially in low birth weight or premature infants due to the higher risk of serum osmolarity increase and intracerebral hemorrhage requiring careful management. Elderly patients, due to decreased bodily function, require special caution during administration. Excessive doses may lead to hyperglycemia or symptoms of diabetes, potentially necessitating insulin administration. Subcutaneous injections may lead to local irritation and circulatory failure, hence should be avoided. After opening, the remaining solution should be disposed of immediately and care should be taken against infection risks when infusing. Use warm by bringing to body temperature if stored in low temperatures, and abrupt cessation after high-concentration solution administration may cause hypoglycemia. Avoid administering with blood simultaneously, and if mixing with other drugs, ensure thorough awareness of potential chemical and physical reactions and monitor carefully. To reduce the risk of air embolism due to air in the container, continuous connection administration should be avoided.

Serious side effects

Adverse reactions due to glass particle contamination, potential for severe allergic reactions, potential for severe skin reactions, risk of thrombophlebitis with hypertonic solution administration, severe edema or urination abnormalities, hyperosmolar coma, hyperglycemia and renal loss due to glucose intolerance, fetal hyperglycemia and metabolic acidosis, seizure due to neonatal hypoglycemia, coma, risk of brain damage, serious neurological symptoms, thrombosis, blood leak

Mild side effects

• Hypokalemia
• hyperosmolar coma
• acidosis
• dehydration
• hyperosmolarity
• polyuria with glucose detection
• fluid or solute overload
• fluid-electrolyte imbalance
• congestion
• pulmonary edema

This drug should be stored in a sealed container to prevent air and moisture ingress, avoiding direct sunlight, and should ideally be kept at room temperature. Room temperature refers to temperatures generally between 15 degrees and 25 degrees Celsius, avoiding extremes of heat or cold.

Appearance

A colorless and transparent intravenous solution filled in a container made of high-density polyethylene, which is wrapped in translucent packaging.

Package unit

1000 milliliters